Verified Sponsor Execution & Regulatory Ledger
| Sponsor Metric | Verified Count / Rate |
|---|---|
| Phase II & III Protocols (2018 to 2026) | 19 |
| Active Pipeline (Recruiting Now) | 19 (15) |
| Completed vs Stopped Early | 0 / 0 (0.0%) |
| Median Closed Actual Enrollment | Not reported |
| Physical Hospital Site Disclosure | 61.9% named hospitals |
| FDA Drugs@FDA Original NDA/BLA Approvals | 0 (0 since 2018) |
Top Partner U.S. Hospital Clinical Research Sites
| Hospital Research Site | Location | Shared Protocols |
|---|---|---|
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong | 9 |
| Fudan University Shanghai Cancer Center | Shanghai, Shanghai Municipality | 5 |
| Harbin Medical University Cancer Hospital | Harbin, Heilongjiang | 4 |
Indexed Multi-Center Phase II & III Protocols
| NCT Identifier | Protocol Brief Title | Phase | Status |
|---|---|---|---|
| NCT06107686 | A Study of YL202 in Selected Patients With Advanced Solid Tumors | Phase II | RECRUITING |
| NCT06241846 | A Phase II Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of YL201 in Patients With mCRPC | Phase II | RECRUITING |
Explore interactive annual charts and M&A subsidiary rollups in the MediLink Therapeutics (Suzhou) Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.